Skip to main content
. Author manuscript; available in PMC: 2021 Jul 18.
Published in final edited form as: Nat Med. 2020 May 11;26(5):693–698. doi: 10.1038/s41591-020-0860-1

Figure 1. Plasma IL8 and clinical outcomes in metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC).

Figure 1.

a, High baseline plasma IL8 (pIL8) levels (median cutoff: 15 pg/mL) were significantly associated with worse overall survival (OS) in cohort 2 of IMvigor210 (HR=1.84, 95% CI: 1.27, 2.66, P=1.2e-3). b, High baseline pIL8 levels were associated with a higher number of nonresponders (SD and PD) (P= 0.013, two-sided Fisher’s exact test) by Response Evaluation Criteria in Solid Tumors (RECIST) 2.1. [CR: complete response; PR, partial response; SD, stable disease; PD, progressive disease]. c, High baseline pIL8 was associated with poor OS in tumors with a T effector infiltrate signature (CD8A, GZMA, GZMB, PRF1) in mUC patients in cohort 2 of IMvigor210 (HR: 1.84; 95% CI: 1.27, 2.66, P=0.010). d, In a randomized mUC Phase 3 trial, IMvigor211, high baseline pIL8 levels were associated with worse OS in both the atezolizumab (HR: 1.84; 95% CI: 1.8, 2.26, P=4.74e-5) and chemotherapy (HR: 1.67; 95% CI: 1.38, 2.03, P=1.08e-7) treatment arms. e, Kaplan–Meier curves depict median overall survival in the atezolizumab (atezo) + bevacizumab (bev), atezolizumab monotherapy, and sunitinib treatment arms. High baseline pIL8 was associated with worse OS in the atezolizumab (HR: 2.55, 95% CI: 1.18, 5.5, P=0.017) arm but not atezolizumab + bevacizumab (HR: 1.25, 95% CI: 0.61, 2.60, P=0.535) and sunitinib arm (HR: 1.48, 95% CI: 0.69, 3.20, P=0.314) in a randomized mRCC Phase 2 trial, IMmotion150. HRs in Figure 1a,c-e were calculated using stratified Cox proportional hazard regression models, and P values were calculated using stratified log-rank test. P values were adjusted for multiple comparisons. Multivariate analyses adjusted HRs for age, sex, race, ECOG performance status, presence of liver metastasis, and tumor burden (sum of longest diameter, SLD) in mUC; age, sex, Memorial Sloan Kettering Cancer Risk (MSKCC) prognostic risk score, previous nephrectomy, and SLD in mRCC data sets.